Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.

Dee Shortridge Lalitagauri M Deshpande Jennifer M Streit Mariana Castanheira

Published in: JAC-antimicrobial resistance (2022)

activity against CRE isolates that lacked known carbapenemases. Resistance mechanisms observed among nonCP CREs included acquired β-lactamases and OMP alterations. These results indicate that meropenem/vaborbactam may be a useful treatment for infections caused by nonCP CREs.

Keyphrases

gram negative
klebsiella pneumoniae
multidrug resistant
acinetobacter baumannii
cystic fibrosis
combination therapy